Thomas Mandrup-Poulsen

Summary

Country: Denmark

Publications

  1. pmc Anti-inflammatory properties of a novel peptide interleukin 1 receptor antagonist
    Boris Klementiev
    Laboratory of Neural Plasticity, Department of Neuroscience and Pharmacology, University of Copenhagen, Blegdamsvej 3, DK 2200 Copenhagen, Denmark
    J Neuroinflammation 11:27. 2014
  2. ncbi Interleukin-1 antagonists for diabetes
    Thomas Mandrup-Poulsen
    University of Copenhagen, Panum Institute 12 2 10, Faculty of Health and Medical Sciences, Department of Biomedical Sciences, Section for Endocrinological Research, Blegdamsvej 3, DK 2200 Copenhagen N, Denmark
    Expert Opin Investig Drugs 22:965-79. 2013
  3. pmc Interleukin-1 antagonists and other cytokine blockade strategies for type 1 diabetes
    Thomas Mandrup-Poulsen
    Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, DK 2200 Copenhagen, Denmark
    Rev Diabet Stud 9:338-47. 2012
  4. ncbi Type 2 diabetes mellitus: a metabolic autoinflammatory disease
    Thomas Mandrup-Poulsen
    Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, 3 Blegdamsvej, DK 2200 Copenhagen N, Denmark
    Dermatol Clin 31:495-506. 2013

Collaborators

  • Boris Klementiev
  • Peter S Walmod
  • Morten Lundh
  • Dan P Christensen
  • Oksana Dmytriyeva
  • Laura K Kjær
  • Elisabeth Bock
  • Shizhong Li
  • Vladimir Berezin
  • Mattias S Dahllöf
  • Stanislava Pankratova
  • Irina Korshunova

Detail Information

Publications5

  1. pmc Anti-inflammatory properties of a novel peptide interleukin 1 receptor antagonist
    Boris Klementiev
    Laboratory of Neural Plasticity, Department of Neuroscience and Pharmacology, University of Copenhagen, Blegdamsvej 3, DK 2200 Copenhagen, Denmark
    J Neuroinflammation 11:27. 2014
    ..Interleukin 1 (IL-1) is implicated in neuroinflammation, an essential component of neurodegeneration. We evaluated the potential anti-inflammatory effect of a novel peptide antagonist of IL-1 signaling, Ilantide...
  2. ncbi Interleukin-1 antagonists for diabetes
    Thomas Mandrup-Poulsen
    University of Copenhagen, Panum Institute 12 2 10, Faculty of Health and Medical Sciences, Department of Biomedical Sciences, Section for Endocrinological Research, Blegdamsvej 3, DK 2200 Copenhagen N, Denmark
    Expert Opin Investig Drugs 22:965-79. 2013
    ..There is an unmet need for interventions targeting pathogenetic mechanisms in diabetes, and the market for such therapies is huge...
  3. pmc Interleukin-1 antagonists and other cytokine blockade strategies for type 1 diabetes
    Thomas Mandrup-Poulsen
    Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, DK 2200 Copenhagen, Denmark
    Rev Diabet Stud 9:338-47. 2012
    ....
  4. ncbi Type 2 diabetes mellitus: a metabolic autoinflammatory disease
    Thomas Mandrup-Poulsen
    Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, 3 Blegdamsvej, DK 2200 Copenhagen N, Denmark
    Dermatol Clin 31:495-506. 2013
    ..It is hoped that targeting these mechanisms will enable the introduction of novel therapies that attack the basic pathogenetic mechanisms of type 2 diabetes mellitus rather than the epiphenomena that are its consequences. ..